Epigenetics in prostate cancer treatment.
Epigenetics in prostate cancer treatment.
复制标题
DOI：
10.20517/jtgg.2021.19
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Liu J
中科院分区：
文献类型：
--
作者：
Jones K;Zhang Y;Kong Y;Farah E;Wang R;Li C;Wang X;Zhang Z;Wang J;Mao F;Liu X;Liu J
前列腺癌（PCa）是男性中最常见的恶性肿瘤，这种疾病的进展导致临床患者可获得的治疗选择较少。它强调了发现新的治疗方法和扩大目前对分子机制的理解的至关重要的必要性。表观遗传改变，如DNA甲基化模型和组蛋白修饰，被认为是前列腺癌发展和进展的关键驱动因素。一些研究已经进行并证明，靶向这些表观遗传酶或调节蛋白与癌细胞生长的调节密切相关。由于这些治疗途径在临床前环境中的成功率，许多药物现在已经进入临床试验阶段，在那里将测量疗效。本文将讨论表观遗传修饰在前列腺癌发展中的作用及其在疾病向耐药形式发展中的作用，并介绍已经证明成功治疗前列腺癌的治疗策略。
Prostate cancer (PCa) is the most commonly diagnosed malignancy among men, and the progression of this disease results in fewer treatment options available to clinical patients. It highlights the vital necessity for discovering novel therapeutic approaches and expanding the current understanding of molecular mechanisms. Epigenetic alternations such as DNA methylation models and histone modifications have been associated as key drivers in the development and advancement of PCa. Several studies have been conducted and demonstrated that targeting these epigenetic enzymes or regulatory proteins has been strongly associated with the regulation of cancer cell growth. Due to the success rate of these therapeutic routes in pre-clinical settings, many drugs have now advanced to clinical testing, where efficacy will be measured. This review will discuss the role of epigenetic modifications in PCa development and its function in the progression of the disease to resistant forms and introduce therapeutic strategies that have demonstrated successful results as PCa treatment.